Compare Campbell Soup Co. (CPB) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs Pfizer Inc — how do they compare? Campbell Soup Co. trades at $19.31 (market cap $5.78B), while Pfizer Inc trades at $27.81 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 27.4× Campbell Soup Co.'s market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Campbell Soup Co. for 98 Days and Pfizer Inc for 158 Days on average.
| CPB | PFE | |
|---|---|---|
Market Cap | $5.78B | $158.56B |
Volume | 11,705,427 | 44,138,282 |
Sector | Consumer Staples | Health |
52-Week High | $31.66 | $29.02 |
52-Week Low | $18.90 | $23.67 |
Typical Hold Time | 98 Days | 158 Days |
Enterprise Value | $12.83B | $210.06B |
Dividend Yield | 5.16% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's stock trades at $18.90, down 0.53% with bearish technical indicators. The company faces margin compression with net income margin at 4.14% and recently cut its dividend by 36% to strengthen the balance sheet. Revenue grew to $10.25B in 2025 but profitability remains under pressure. Analyst consensus shows cautious sentiment with 55% hold ratings and a $19.67 price target.
The outlook remains challenging with weak FY2027 guidance and ongoing restructuring. The $500 million cost savings program and Rao's brand growth offer potential upside, but investors face risks from declining sales, margin pressure, and competitive headwinds in the packaged foods sector.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
